{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:33:12Z","timestamp":1769531592625,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03189-z","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:17:11Z","timestamp":1765433831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is escalated BEACOPP dead? Rethinking standards in hodgkin lymphoma treatment"],"prefix":"10.1007","volume":"43","author":[{"given":"Colette","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-5521","authenticated-orcid":false,"given":"Fouad","family":"Attieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2502-5402","authenticated-orcid":false,"given":"Hampig Rapha\u00ebl","family":"Kourie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"3189_CR1","unstructured":"Hodgkin Lymphoma - Cancer Stat Facts. https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html"},{"key":"3189_CR2","doi-asserted-by":"publisher","first-page":"20500","DOI":"10.1038\/s41598-024-69975-3","volume":"14","author":"A Aslani","year":"2024","unstructured":"Aslani A, Morsali S, Mousavi SE, Choupani S, Yekta Z, Nejadghaderi SA. Adult hodgkin lymphoma incidence trends in the united States from 2000 to 2020. Sci Rep. 2024;14:20500. https:\/\/doi.org\/10.1038\/s41598-024-69975-3.","journal-title":"Sci Rep"},{"key":"3189_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00277","volume":"0","author":"JG Schroers-Martin","year":"2024","unstructured":"Schroers-Martin JG, Advani R. Integrating novel agents into the clinical management of classic Hodgkin lymphoma. JCO Oncol Pract. 2024;0:00277. https:\/\/doi.org\/10.1200\/OP.24.00277.","journal-title":"JCO Oncol Pract"},{"issue":"Suppl 5","key":"3189_CR4","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1093\/annonc\/9.suppl_5.s73","volume":"9","author":"M Loeffler","year":"1998","unstructured":"Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin\u2019s disease. German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol Off J Eur Soc Med Oncol. 1998;9(Suppl 5):S73-78. https:\/\/doi.org\/10.1093\/annonc\/9.suppl_5.s73.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3189_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF01697624","volume":"66","author":"V Diehl","year":"1993","unstructured":"Diehl V. Dose-escalation study for the treatment of hodgkin\u2019s disease. The German hodgkin study group (GHSG). Ann Hematol. 1993;66:139\u201340. https:\/\/doi.org\/10.1007\/BF01697624.","journal-title":"Ann Hematol"},{"key":"3189_CR6","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.19.03160","volume":"38","author":"S Kreissl","year":"2020","unstructured":"Kreissl S, M\u00fcller H, Goergen H, Meissner J, Topp M, S\u00f6kler M, et al. Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group. J Clin Oncol. 2020;38:2839\u201348. https:\/\/doi.org\/10.1200\/JCO.19.03160.","journal-title":"J Clin Oncol"},{"key":"3189_CR7","doi-asserted-by":"publisher","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","volume":"29","author":"DA Eichenauer","year":"2018","unstructured":"Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2018;29:iv19\u201329. https:\/\/doi.org\/10.1093\/annonc\/mdy080.","journal-title":"Ann Oncol"},{"key":"3189_CR8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.38.0410.","journal-title":"J Clin Oncol"},{"key":"3189_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","volume":"404","author":"P Borchmann","year":"2024","unstructured":"Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024;404:341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)01315-1.","journal-title":"Lancet"},{"key":"3189_CR10","unstructured":"Inc MG, Treatment effects of brecadd on health-related quality of life:\u00a0An... by Justin Ferdinandus. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/419187\/justin.ferdinandus.treatment.effects.of.brecadd.on.health-related.quality.of.html"},{"key":"3189_CR11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2024-200211","volume":"144","author":"F Kristo","year":"2024","unstructured":"Kristo F, Mazerolle F, Alin T, Regnault A, Ferdinandus J, Behringer K, et al. Patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in advanced-stage classical hodgkin lymphoma treated with BrECADD and eBEACOPP in the HD21 trial. Blood. 2024;144:1662. https:\/\/doi.org\/10.1182\/blood-2024-200211.","journal-title":"Blood"},{"key":"3189_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim W-S, Gallamini A, et al. Overall survival with brentuximab vedotin in stage III or IV hodgkin\u2019s lymphoma. N Engl J Med. 2022;387:310\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2206125.","journal-title":"N Engl J Med"},{"key":"3189_CR13","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1182\/blood-2024-203089","volume":"144","author":"A Almuqbil","year":"2024","unstructured":"Almuqbil A, Alrajhi A, Alshehri H, Motabi IH, Tailor IK, Alzahrani K, Marei M, Alnoamani MS, Alshehry NF, Alhumaid M. Bv-AVD esclation after partial response to ABVD chemotherapy in patinets with HL: A retrospective study. Blood. 2024;144:6373. https:\/\/doi.org\/10.1182\/blood-2024-203089.","journal-title":"Blood"},{"key":"3189_CR14","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O\u2019Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377. https:\/\/doi.org\/10.1182\/blood-2010-05-282780.","journal-title":"Blood"},{"key":"3189_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg JW. Nivolumab\u2009+\u2009AVD in Advanced-Stage classic hodgkin\u2019s lymphoma. N Engl J Med. 2024;391:1379\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2405888.","journal-title":"N Engl J Med"},{"key":"3189_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/bloodadvances.2022008116","volume":"7","author":"PB Allen","year":"2023","unstructured":"Allen PB, Lu X, Chen Q, O\u2019Shea K, Chmiel JS, Slonim LB, Sukhanova M, Savas H, Evens AM, Advani R, Pro B, Karmali R, Palmer B, Bayer RA, Eisner RM, Mou E, Dillehay G, Gordon LI, Winter JN. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated hodgkin lymphoma. Blood Adv. 2023;7:2670\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2022008116.","journal-title":"Blood Adv"},{"key":"3189_CR17","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1182\/blood.2020007400","volume":"137","author":"PB Allen","year":"2021","unstructured":"Allen PB, Savas H, Evens AM, Advani RH, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer RA, Eisner RM, Chmiel JS, O\u2019Shea K, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical hodgkin lymphoma. Blood. 2021;137:1318\u201326. https:\/\/doi.org\/10.1182\/blood.2020007400.","journal-title":"Blood"},{"key":"3189_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1470-2045(24)00598-9","volume":"26","author":"A Santarsieri","year":"2025","unstructured":"Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, et al. The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study. Lancet Oncol. 2025;26:98\u2013109. https:\/\/doi.org\/10.1016\/S1470-2045(24)00598-9.","journal-title":"Lancet Oncol"},{"key":"3189_CR19","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, H\u00fcttmann A, Dierlamm J, Soekler M, Beck H-J, Willenbacher W, Ludwig W-D, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, K\u00fchnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German hodgkin study group. Lancet Lond Engl. 2017;390:2790\u2013802. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7.","journal-title":"Lancet Lond Engl"},{"key":"3189_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35:1786\u201394. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394.","journal-title":"J. Clin. Oncol."},{"key":"3189_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.23.01745","volume":"42","author":"M Federico","year":"2024","unstructured":"Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, et al. Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin Lymphoma. J Clin Oncol. 2024;42:19\u201325. https:\/\/doi.org\/10.1200\/JCO.23.01745.","journal-title":"J Clin Oncol"},{"key":"3189_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"L-M Fornecker","year":"2023","unstructured":"Fornecker L-M, Lazarovici J, Aurer I, Casasnovas R-O, Gac A-C, Bonnet C, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin Lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial. J Clin Oncol. 2023;41:327\u201335. https:\/\/doi.org\/10.1200\/JCO.21.01281.","journal-title":"J Clin Oncol"},{"key":"3189_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2023-172574","volume":"142","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN\u2009+\u2009AD) for early-stage classical hodgkin lymphoma (SGN35-027 part C). Blood. 2023;142:611. https:\/\/doi.org\/10.1182\/blood-2023-172574.","journal-title":"Blood"},{"key":"3189_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2024-202207","volume":"144","author":"SI Park","year":"2024","unstructured":"Park SI, Ansell SM, Boselli D, Giri S, Svoboda J, Smith SD, et al. PET-directed therapy with ABVD vs. Bv\u2009+\u2009AVD followed by nivolumab in patients with early stage hodgkin lymphoma: a propensity score matched analysis of CALGB50604 and ACCRULY1601. Blood. 2024;144:458. https:\/\/doi.org\/10.1182\/blood-2024-202207.","journal-title":"Blood"},{"key":"3189_CR25","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1182\/blood-2023-189652","volume":"142","author":"TO Henderson","year":"2023","unstructured":"Henderson TO, Hu B, Keller F, Pei Q, Wu Y, Hoppe B, et al. AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic hodgkin lymphoma. Blood. 2023;142:3084. https:\/\/doi.org\/10.1182\/blood-2023-189652.","journal-title":"Blood"},{"key":"3189_CR26","unstructured":"National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"3189_CR27","doi-asserted-by":"publisher","unstructured":"S V. Hodgkin lymphoma therapy: minimising clinical and biological harms. Lancet Oncol. 2025;26. https:\/\/doi.org\/10.1016\/S1470-2045(24)00655-7.","DOI":"10.1016\/S1470-2045(24)00655-7"},{"key":"3189_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002347","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma. J Immunother Cancer. 2021;9:e002347. https:\/\/doi.org\/10.1136\/jitc-2021-002347.","journal-title":"J Immunother Cancer"},{"key":"3189_CR29","doi-asserted-by":"publisher","first-page":"7545","DOI":"10.1200\/JCO.2022.40.16_suppl.7545","volume":"40","author":"J Timmerman","year":"2022","unstructured":"Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory G, Keane C, Inna T, Vucinic V, Zinzani PL, Zhang H, Pillai P, Marinello P, Herrera AF. Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with relapsed or refractory (R\/R) classical hodgkin lymphoma (cHL) after anti\u2013PD-1 treatment: an open-label phase 1\/2 study. J Clin Oncol. 2022;40:7545\u20137545. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7545.","journal-title":"J Clin Oncol"},{"key":"3189_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1378647","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J. Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives. Front Oncol. 2024;14:1378647. https:\/\/doi.org\/10.3389\/fonc.2024.1378647.","journal-title":"Front Oncol"},{"key":"3189_CR31","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2025.43.16_suppl.7008","volume":"43","author":"JE Maakaron","year":"2025","unstructured":"Maakaron JE, Feldman TA, Fehniger TA, Shah GL, Mehta A, Modi D, Mei MG, Sauter C, Khanal R, Barta SK, Maly J, Emig M, Wunderle L, Overesch A, Pietzko K, Vasile A, Rubel J, Graef T, Raymon H, Moskowitz AJ. Results from the completed dose-finding part of phase 2 study of the innate cell engager Acimtamig (AFM13) in combination with allonk (AB-101) in relapsed or refractory classical hodgkin lymphoma (LuminICE-203). J Clin Oncol. 2025;43:7008\u20137008. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7008.","journal-title":"J Clin Oncol"},{"key":"3189_CR32","doi-asserted-by":"publisher","first-page":"e971","DOI":"10.1097\/HS9.0000000000000971","volume":"7","author":"M Katsin","year":"2023","unstructured":"Katsin M, Dormeshkin D, Meleshko A, Migas A, Dubovik S, Konoplya N. CAR-T cell therapy for classical hodgkin lymphoma. HemaSphere. 2023;7:e971. https:\/\/doi.org\/10.1097\/HS9.0000000000000971.","journal-title":"HemaSphere"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03189-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03189-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:50:11Z","timestamp":1769485811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03189-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3189"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03189-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"43"}}